HK1211297A1 - Binding proteins comprising at least two repeat domains against her2 her2 - Google Patents

Binding proteins comprising at least two repeat domains against her2 her2

Info

Publication number
HK1211297A1
HK1211297A1 HK15110090.1A HK15110090A HK1211297A1 HK 1211297 A1 HK1211297 A1 HK 1211297A1 HK 15110090 A HK15110090 A HK 15110090A HK 1211297 A1 HK1211297 A1 HK 1211297A1
Authority
HK
Hong Kong
Prior art keywords
her2
binding proteins
repeat domains
domains against
against her2
Prior art date
Application number
HK15110090.1A
Other languages
English (en)
Chinese (zh)
Inventor
烏爾麗克‧菲德勒
伊格納西奧‧多拉多
海克‧施特羅貝爾
Original Assignee
Molecular Partners Ag
14 Ch 8952
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag, 14 Ch 8952 filed Critical Molecular Partners Ag
Publication of HK1211297A1 publication Critical patent/HK1211297A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
HK15110090.1A 2012-11-30 2015-10-15 Binding proteins comprising at least two repeat domains against her2 her2 HK1211297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (1)

Publication Number Publication Date
HK1211297A1 true HK1211297A1 (en) 2016-05-20

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110090.1A HK1211297A1 (en) 2012-11-30 2015-10-15 Binding proteins comprising at least two repeat domains against her2 her2

Country Status (11)

Country Link
US (1) US10370414B2 (es)
EP (2) EP2738180A1 (es)
JP (1) JP6410724B2 (es)
KR (1) KR102290592B1 (es)
CN (1) CN104918959A (es)
AU (2) AU2013351096C9 (es)
CA (1) CA2892747C (es)
HK (1) HK1211297A1 (es)
MX (1) MX366223B (es)
RU (1) RU2664464C9 (es)
WO (1) WO2014083208A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) * 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
US10093740B2 (en) * 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
KR102064396B1 (ko) 2015-07-16 2020-01-09 나피고 프로타인스 게엠베하 신규한 면역글로불린-결합 단백질 및 친화도 정제에서의 이의 용도
CA2991814A1 (en) * 2015-07-20 2017-01-26 Navigo Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
WO2017013136A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
CA3022751A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
AU2017311541B2 (en) 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
MX2019003298A (es) * 2016-09-22 2019-09-26 Molecular Partners Ag Proteinas de union recombinantes y sus usos.
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
BR112021024231A2 (pt) * 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
WO2020245171A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
US20220298212A1 (en) * 2019-06-04 2022-09-22 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
AU2020399230A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Recombinant peptide-MHC complex binding proteins and their generation and use
CR20220618A (es) 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
AU2022231913A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd33 engagers
MX2023010543A (es) 2021-03-09 2023-10-13 Molecular Partners Ag Ligadores multiespecificos de celulas t novedosos basados en darpin.
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
JP4086325B2 (ja) 1997-04-23 2008-05-14 プリュックテュン,アンドレアス 標的分子と相互作用する(ポリ)ペプチドをコードする核酸分子の同定方法
US6416950B1 (en) 1998-12-02 2002-07-09 Phylos, Inc. DNA-protein fusions and uses thereof
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US8124085B2 (en) * 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
JP2008507520A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド Her2抗体組成物
NZ564695A (en) 2005-07-08 2009-02-28 Univ Zuerich Phage display using cotranslational translocation of fusion polypeptides
WO2007103455A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag Vegf−aレセプター相互作用を阻害する結合タンパク質
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818990C (en) 2010-11-26 2021-06-15 Molecular Partners Ag Designed repeat proteins binding to serum albumin
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Also Published As

Publication number Publication date
WO2014083208A9 (en) 2014-12-24
US10370414B2 (en) 2019-08-06
EP2738180A1 (en) 2014-06-04
WO2014083208A8 (en) 2014-10-30
KR20150091138A (ko) 2015-08-07
CA2892747A1 (en) 2014-06-05
CN104918959A (zh) 2015-09-16
AU2018256592A1 (en) 2018-11-22
CA2892747C (en) 2022-07-19
US20150299265A1 (en) 2015-10-22
EP2925784B1 (en) 2021-02-17
AU2013351096C1 (en) 2018-11-08
RU2664464C2 (ru) 2018-08-17
MX2015006548A (es) 2015-10-15
MX366223B (es) 2019-07-03
WO2014083208A1 (en) 2014-06-05
EP2925784A1 (en) 2015-10-07
BR112015012436A2 (pt) 2017-09-12
RU2664464C9 (ru) 2018-12-19
AU2013351096B2 (en) 2018-08-09
JP6410724B2 (ja) 2018-10-24
KR102290592B1 (ko) 2021-08-19
RU2015120663A (ru) 2017-01-10
JP2015537044A (ja) 2015-12-24
AU2013351096C9 (en) 2019-01-31
AU2013351096A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
HK1211297A1 (en) Binding proteins comprising at least two repeat domains against her2 her2
IL282226A (en) ST2 antigen-binding proteins
HK1216894A1 (zh) 多價結合蛋白組合物
IL240838A0 (en) Anti-3–lag binding proteins
HK1212711A1 (zh) 抗原結合蛋白
IL254652A0 (en) Unnatural albumin binding sites
IL240915A0 (en) Dual-specific binding proteins directed against tnfɑ
HK1214167A1 (zh) 結合的抗感染結合蛋白
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201200563D0 (en) Binding molecule
EP2817324A4 (en) NEMO BOND DOMAIN FUSION PROTEINS
GB201215901D0 (en) Protein modification
GB201213672D0 (en) Protein
GB201200743D0 (en) Protein bridges